ABVX

AbivaxC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-21

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$185.00

+38.0% vs current

Most likely

Base case

45%

Probability

Target price

$150.00

+11.9% vs current

B-

Bear case

35%

Probability

Target price

$35.00

-73.9% vs current

AI sentiment snapshot

Latest data as of 2026-06-03

AI commentary

Sentiment is dominated by the June 2 selloff after trusted-news reports highlighted cancer-case concerns, while company releases confirmed strong ABTECT efficacy and stated no new safety signals. Because the packet lacks post-event analyst revisions and the primary company release does not directly resolve the market's malignancy concern, this remains a cautious, monitoring-focused negative view rather than a high-conviction short thesis.

RankAlpha Sentiment Codex - 2026-06-03

Open full AI memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-06-06catalystPost-ABTECT safety digestion drives near-term volatilityHigh impact

Abivax's June 1 company release reported positive Phase 3 ABTECT maintenance results at Week 44, with both 25 mg and 50 mg obefazimod meeting the primary endpoint and key secondary endpoints and with no new safety signals observed; however, the June 2 selloff tied to third-party cancer-case reporting leaves near-term trading dominated by safety interpretation rather than efficacy alone [#PR-ABIVAX-2026-06-01].

2026-12-31eventLate-Q4 2026 NDA path remains the next binary milestoneHigh impact

The company release said Abivax intends to submit an NDA to the FDA in late Q4 2026, so the next major value checkpoint is whether ABTECT safety and efficacy data remain sufficient to support that filing path [#PR-ABIVAX-2026-06-01].

2027-03-31catalystStudy 108 durability and runway support the thesis only if safety clearsHigh impact

The May 22 company release reported Q1 results, three-year interim Study 108 data, cash and short-term investments of €491.6M as of March 31, 2026, and projected runway into Q4 2027; those factors support continued development, but do not remove the single-asset and safety-overhang risk [#PR-ABIVAX-2026-05-22].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-06-03 • Updated nightlySource: Internal modelMethodology